Page last updated: 2024-10-24

regulation of G0 to G1 transition

Definition

Target type: biologicalprocess

A cell cycle process that modulates the rate or extent of the transition from the G0 quiescent state to the G1 phase. [GOC:mah]

The G0 to G1 transition, a crucial step in the cell cycle, is tightly regulated to ensure proper cell growth and division. This transition marks the commitment of a cell to enter the active cell cycle and replicate. Here's a detailed breakdown of the biological process:

**1. Cell in G0 Phase:**
- Cells in G0 are quiescent, not actively dividing. They have exited the cell cycle and are metabolically active but not replicating their DNA or preparing for division.
- This phase can be a temporary resting state or a permanent withdrawal from the cell cycle, depending on the cell type.

**2. Signals for G0 to G1 Transition:**
- The transition from G0 to G1 is triggered by specific growth factors and extracellular signals.
- These signals can be mitogens, nutrients, or other environmental cues that indicate favorable conditions for cell proliferation.
- Examples of such signals include epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and insulin.

**3. Receptor Activation and Signal Transduction:**
- Growth factors bind to their specific receptors on the cell surface, initiating a cascade of intracellular signaling events.
- Receptor activation leads to the phosphorylation of downstream signaling molecules, such as Ras, MAP kinases (MAPKs), and PI3K.
- These signaling pathways converge on specific transcription factors, including Myc and E2F, which are key regulators of the G1 phase.

**4. Cyclin-Dependent Kinases (CDKs) Activation:**
- The activated transcription factors upregulate the expression of cyclins and cyclin-dependent kinases (CDKs), which are essential for the G1 phase progression.
- CDKs are enzymes that control the cell cycle by phosphorylating specific target proteins.
- The activation of CDKs requires the binding of cyclins, which act as regulatory subunits.
- There are multiple CDKs and cyclins involved in the G1 phase, including CDK4/6 and cyclin D, CDK2 and cyclin E.

**5. Retinoblastoma Protein (Rb) Phosphorylation:**
- Activated CDK4/6 complexes phosphorylate the retinoblastoma protein (Rb), a key tumor suppressor protein.
- Rb is a negative regulator of the cell cycle, preventing the entry into S phase by inhibiting E2F transcription factors.
- Phosphorylation of Rb leads to its inactivation, releasing E2F to activate the transcription of genes required for DNA replication and cell cycle progression.

**6. G1 Checkpoint:**
- The G1 checkpoint ensures that the cell has adequate resources and is ready for DNA replication.
- This checkpoint monitors DNA integrity, nutrient availability, and cell size.
- If the cell fails to meet the requirements of the G1 checkpoint, it may be delayed in the G1 phase or even arrested in the cell cycle.

**7. Entry into S Phase:**
- After passing the G1 checkpoint, the cell enters the S phase, where DNA replication takes place.
- CDK2 and cyclin E play crucial roles in the transition from G1 to S phase.
- The activated CDK2/cyclin E complex further phosphorylates Rb and activates other key S phase regulators.

**8. Regulation of G0 to G1 Transition:**
- The regulation of the G0 to G1 transition is complex and involves a network of interconnected signaling pathways and feedback loops.
- It is influenced by factors such as cell type, growth conditions, and cell-cell interactions.
- Dysregulation of this process can lead to uncontrolled cell proliferation and contribute to cancer development.

**9. G1 Phase Progression:**
- Once the cell enters G1, it continues to grow and accumulate necessary resources for DNA replication.
- The G1 phase is also a time for protein synthesis and organelle replication.

**Conclusion:** The G0 to G1 transition is a critical step in the cell cycle, tightly controlled by multiple signaling pathways and regulatory proteins. This process ensures that cells only enter the cell cycle when conditions are favorable and all necessary resources are available. Understanding the intricacies of this transition is crucial for comprehending normal cell growth and development, as well as the mechanisms underlying cell cycle dysregulation in diseases such as cancer.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Bromodomain-containing protein 7A bromodomain-containing protein 7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NPI1]Homo sapiens (human)
Protein polybromo-1A protein polybromo-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q86U86]Homo sapiens (human)
Transcription activator BRG1A transcription activator BRG1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P51532]Homo sapiens (human)
Probable global transcription activator SNF2L2A probable global transcription activator SNF2L2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P51531]Homo sapiens (human)

Compounds (10)

CompoundDefinitionClassesRoles
lobenzaritlobenzarit: prevents autoimmune kidney disease in hybrid mice; RN given refers to parent cpdaminobenzoic acid
3-acetylindole3-acetylindole: structure in first source
tg 003TG 003: a Clk inhibitor; structure in first source
2,4-Di(3-pyridyl)-1,3-thiazolethiazoles
5-Methyl-6-(2-thienyl)-2,3,4,5-tetrahydropyridazin-3-onepyridazines
luteolin3'-hydroxyflavonoid;
tetrahydroxyflavone
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
i-bet726
pf-06687252PF-06687252: a SMARCA2/4 bromodomain inhibitor; structure in first source

PFI-3 : An azabicycloalkane that is (1R,4R)-2,5-diazabicyclo[2.2.1]heptane which is substituted at position 2 by a 3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl group and at position 5 by a pyridin-2-yl group. It is a potent and selective inhibitor of polybromo 1 (Kd = 48 nM), SMARCA2 and SMARCA4 (Kd = 89 nM) bromodomains.
azabicycloalkane;
enone;
phenols;
pyridines
pf-477736PF 00477736: a Chk1 inhibitor; structure in first source

PF-00477736 : A diazepinoindole that is 8-amino-4,5-dihydro-6H-[1,2]diazepino[4,5,6-cd]indol-6-one which is substituted at position 2 by a 1-methylpyrazol-4-yl group and in which the amino group at position 8 has undergone condensation with the carboxy group of (2R)-2-cyclohexylglycine to give the corresponding carboxamide. It is an inhibitor of checkpoint kinase 1 (Chk 1).